Thus, it is conceivable that RYGB may reverse blunted ghrelin signaling in obesity [34], [35], which acting upstream on the dopamine neurons [36], [37], [38], may alleviate reward deficits associated with dietary obesity [39]. The gene discussed is GHRL; the disease is obesity disorder.